Skip to main content

Table 1 Demographic and clinical characteristics of prostate cancer patients by tumor TMPRSS2-ERG gene fusion status.

From: Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer

 

TMPRSS2-ERG Gene Fusion Status

Characteristics

Not Scored1

Positive

Negative

 

n = 158

n = 76

n = 138

Age at diagnosis

   

   Mean (SD)

61.2 (7.4)

59.3 (6.3)

59.9 (7.2)

   Range

40 – 86

45 – 88

45 – 86

Gleason score (%)

   

   2 - 7 (3+4)

138 (87.3)

63 (82.9)

115 (83.3)

   7 (4+3) - 10

17 (10.8)

12 (15.8)

19 (13.8)

   Missing

3 (1.9)

1 (1.3)

4 (2.9)

Stage (%)

   

   Local

121 (76.6)

57 (75)

106 (76.8)

   Regional

37 (23.4)

18 (23.7)

29 (21.0)

   Distant

0 (0)

1 (1.3)

3 (2.2)

PSA value at diagnosis (ng/ml) (%)

   

   0 – 9.9

92 (58.2)

52 (68.4)

91 (65.9)

   ≥ 10.0

41 (26.0)

16 (21.1)

29 (21.0)

   Missing

25 (15.8)

8 (10.5)

18 (13.1)

Vital status (%)

   

   Alive

129 (81.7)

65 (85.5)

119 (86.2)

   Deceased

   

Prostate cancer-specific death

4 (2.5)

6 (7.9)

6 (4.4)

Other cause of death

25 (15.8)

5 (6.6)

12 (8.7)

   Missing

0 (0)

0 (0)

1 (0.7)

Fusion Type

   

   Translocation

-

38 (50)

-

   Deletion

-

38 (50)

-

Fusion Number

   

   Single

-

65 (85.5)

-

   Multiple

-

11 (14.5)

-

Survival Time (years) (SD)

11.5 (2.6)

12.0 (2.6)

11.4 (3.1)

  1. 1Includes one equivocal case.